A Phase 3 interventional study of cyclosporine and vehicle of OTX-101 in Keratoconjunctivitis Sicca, sponsored by Sun Pharmaceutical Industries Limited. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-29.
Sponsored by Sun Pharmaceutical Industries Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Keratoconjunctivitis Sicca with a site in United States — none open to participants now, none under way, none of them phase 3. Keratoconjunctivitis Sicca · United States.
Among the 56 studies in Keratoconjunctivitis Sicca with a site in United States, this one is the 5th largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2016, is one of 13 in phase 3, and was the 38th registered.
85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.
Browse Keratoconjunctivitis Sicca studies →None of the 56 studies in Keratoconjunctivitis Sicca with a site in United States is open now. The open studies under Keratoconjunctivitis Sicca, anywhere →
This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 16 · Phase 4 8
First in 1997; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 745 is above the median of 82 across 75 interventional studies indexed under Keratoconjunctivitis Sicca.
Median enrollment 100 across the 52 interventional studies, 203 across the 4 observational. Of the 54 that completed or were terminated, 26 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 56 have an industry lead sponsor. The 10 most frequent:
Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.
Sun Pharmaceutical Industries Limited has 4 studies filed under Keratoconjunctivitis Sicca — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 56 studies in Keratoconjunctivitis Sicca with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
0.09% cyclosporine nanomicellar ophthalmic solution
Drug: cyclosporine
vehicle of OTX-101
Drug: vehicle of OTX-101
Also known as: Seciera
Tear Production
Percentage of Eyes with Increase from Baseline of ≥ 10 mm in Schirmer's Test Score
Time frame: Baseline and 12 weeks
Conjunctival Staining
change from baseline in total conjunctival staining score (lissamine green, modified National Eye Institute scale) at 12 weeks. Conjunctival Lissamine Green Staining Grades ranged from 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots)
Time frame: Baseline and 12 weeks
Central Corneal Staining
change from baseline in central corneal staining score (fluorescein, modified NEI/FDA scale) at 12 weeks. The Expanded National Eye Institute (NEI)/Industry Workshop Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale.
Time frame: Baseline and 12 weeks
Symptom Score
change from baseline in modified Symptom Assessment in Dry Eye (SANDE) score at 12 weeks. A modified SANDE instrument was used to evaluate dry eye symptoms at each visit. Subjects were asked to indicate: 1. frequency of dry and irritated eyes on a scale of 0 (rarely) to 100 (all the time); and 2. severity of dry eyes on a scale of 0 (very mild) to 100 (severe) The global symptom score is the square root of the frequency score times the severity score and will be completed at each visit. (range 0 to 100) Negative change from baseline indicates improvement.
Time frame: Baseline and 12 weeks
| Milestone | OTX-101 0.09% | Vehicle |
|---|---|---|
| Started | 372 | 373 |
| Completed | 347 | 361 |
| Not completed | 25 | 12 |
Percentage of Eyes with Increase from Baseline of ≥ 10 mm in Schirmer's Test Score
| Percentage of eyes | OTX-101 0.09% | Vehicle |
|---|---|---|
| Tear Production | 16.6 | 9.2 |
change from baseline in total conjunctival staining score (lissamine green, modified National Eye Institute scale) at 12 weeks. Conjunctival Lissamine Green Staining Grades ranged from 0 (No punctate stain in zone) to 3 (Densely concentrated micropunctate stain spots)
| score on a scale | OTX-101 0.09% | Vehicle |
|---|---|---|
| Conjunctival Staining | -1.53 ± 1.927 | -1.16 ± 2.2064 |
change from baseline in central corneal staining score (fluorescein, modified NEI/FDA scale) at 12 weeks. The Expanded National Eye Institute (NEI)/Industry Workshop Scale for Corneal Staining Score was used to grade each of the 5 areas of the cornea on a 0 (No punctate stain in area) to 4 (Severe diffuse (coalescent) macropunctate stain of the area) scale.
| score on a scale | OTX-101 0.09% | Vehicle |
|---|---|---|
| Central Corneal Staining | -0.28 ± 0.533 | -0.26 ± 0.588 |
change from baseline in modified Symptom Assessment in Dry Eye (SANDE) score at 12 weeks. A modified SANDE instrument was used to evaluate dry eye symptoms at each visit. Subjects were asked to indicate: 1. frequency of dry and irritated eyes on a scale of 0 (rarely) to 100 (all the time); and 2. severity of dry eyes on a scale of 0 (very mild) to 100 (severe) The global symptom score is the square root of the frequency score times the severity score and will be completed at each visit. (range 0 to 100) Negative change from baseline indicates improvement.
| score on a scale | OTX-101 0.09% | Vehicle |
|---|---|---|
| Symptom Score | -18.8 ± 24.08 | -19.1 ± 23.14 |
Collected over 12 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OTX-101 0.09% | 1/372 (0.3%) | 6/372 (1.6%) | 130/372 (34.9%) |
| Vehicle | 0/372 (0%) | 2/372 (0.5%) | 66/372 (17.7%) |
| Event | OTX-101 0.09% | Vehicle |
|---|---|---|
| DeathGeneral disorders | 1/372 | 0/372 |
| PneumoniaInfections and infestations | 1/372 | 0/372 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/372 | 0/372 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/372 | 0/372 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 1/372 | 0/372 |
| NephrolithiasisRenal and urinary disorders | 1/372 | 0/372 |
| Perforated ulcerGeneral disorders | 0/372 | 1/372 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/372 | 1/372 |
| Event | OTX-101 0.09% | Vehicle |
|---|---|---|
| Instillation site painGeneral disorders | 90/372 | 16/372 |
| Conjunctival hyperaemiaEye disorders | 30/372 | 18/372 |
| HeadacheNervous system disorders | 6/372 | 2/372 |
| BlepharitisEye disorders | 5/372 | 0/372 |
| Eye irritationEye disorders | 3/372 | 5/372 |
| Eye pruritusEye disorders | 1/372 | 5/372 |
| SinusitisEye disorders | 4/372 | 5/372 |
| Foreign body sensation in eyesEye disorders | 1/372 | 5/372 |
| Instillation site lacrimationGeneral disorders | 4/372 | 0/372 |
| Instillation site reactionEye disorders | 4/372 | 2/372 |
Intent to treat population
| Age, Continuous(years) | OTX-101 0.09% | Vehicle | Total |
|---|---|---|---|
| Mean | 58.4 ± 14.10 | 59.5 ± 14.68 | 59.0 ± 14.40 |
| Sex: Female, Male(Participants) | OTX-101 0.09% | Vehicle | Total |
|---|---|---|---|
| Female | 315 | 311 | 626 |
| Male | 56 | 62 | 118 |
| Race (NIH/OMB)(Participants) | OTX-101 0.09% | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 11 | 12 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 41 | 45 | 86 |
| White | 310 | 305 | 615 |
| More than one race | 8 | 10 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2016 to primary completion in Nov 2016, 9 months.
Results were first posted in Apr 2019, 2 years 5 months after primary completion.
Of 12 phase 3 interventional studies under Keratoconjunctivitis Sicca, half reached primary completion within 14 months of starting (the median); a quarter within 7 and three quarters within 18. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine
Sun Pharmaceutical Industries Limited →